ArticleFrontiers in immunology2022

Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3.

Daiki Niizato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.